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Measures of kidney function by 
minimally invasive techniques 
correlate with histological 
glomerular damage in SCID 
mice with adriamycin-induced 
nephropathy
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Maximising the use of preclinical murine models of progressive kidney disease as test beds for 
therapies ideally requires kidney function to be measured repeatedly in a safe, minimally invasive 
manner. To date, most studies of murine nephropathy depend on unreliable markers of renal 
physiological function, exemplified by measuring blood levels of creatinine and urea, and on various 
end points necessitating sacrifice of experimental animals to assess histological damage, thus 
counteracting the principles of Replacement, Refinement and Reduction. Here, we applied two novel 
minimally invasive techniques to measure kidney function in SCID mice with adriamycin-induced 
nephropathy. We employed i) a transcutaneous device that measures the half-life of intravenously 
administered FITC-sinistrin, a molecule cleared by glomerular filtration; and ii) multispectral 
optoacoustic tomography, a photoacoustic imaging device that directly visualises the clearance of 
the near infrared dye, IRDye 800CW carboxylate. Measurements with either technique showed a 
significant impairment of renal function in experimental animals versus controls, with significant 
correlations with the proportion of scarred glomeruli five weeks after induction of injury. These 
technologies provide clinically relevant functional data and should be widely adopted for testing the 
efficacies of novel therapies. Moreover, their use will also lead to a reduction in experimental animal 
numbers.
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Chronic kidney disease (CKD) represents a huge socioeconomic burden, with treatment options for 
severe disease being limited to dialysis and transplantation. By developing regenerative medicine ther-
apies (RMTs) for CKD in preclinical models, novel and alternative clinical approaches may be estab-
lished to halt progression to end stage renal disease (ESRD). In order to maximise the use of preclinical 
murine models of progressive kidney disease as experimentation platforms for novel therapies, including 
drugs and stem cells1–4, kidney function, in concert with structural morphology, needs to be monitored 
repeatedly in a safe, minimally invasive manner. The glomerular filtration rate (GFR) is considered the 
gold standard measure of the main physiological function of the kidney, i.e. to efficiently clear small 
molecular waste products from the blood stream. However, its measurement generally requires repeated 
blood sampling, and for some methods, precisely timed urine collections. While these techniques are 
feasible in patients, it is much more cumbersome and challenging to apply them to small experimental 
animals. To date, therefore, most mouse studies have used surrogate markers of GFR, exemplified by 
measuring blood levels of creatinine and urea. These are unreliable measures of GFR because levels only 
rise when over 50% of renal function is lost; moreover, factors such as food intake can affect blood levels 
independently of GFR. Furthermore, most studies of murine nephropathy have relied heavily on end 
point analysis for the assessment of histological damage, which necessitates killing experimental animals. 
While this provides useful data, the sole reliance on necropsy material is not compatible with optimal 
application of the principles of Replacement, Refinement and Reduction (the 3Rs).
Here, we have evaluated the ability of two minimally invasive in vivo technologies to monitor kidney 
function in an adriamycin (doxorubicin)-induced nephropathy mouse model. The anthracycline antibi-
otic adriamycin (ADR) primarily targets both glomerular endothelium and podocytes in rodents and is 
a model of focal segmental glomerulosclerosis (FSGS), which accounts for 2.3% of all cases of ESRD5. 
The incidence of primary FSGS has increased by up to 13 fold in the last 30 years6. Along with diabetic 
nephropathy, it is a common cause of severe proteinuria. Administration of a single dose of ADR in both 
BALB/c and BALB/c severe combined immunodeficient (SCID) mice leads to two phases of disease4,7–9. 
In the first, glomeruli are grossly histologically intact (i.e. they show no scarring) but their ability to act 
as a macromolecular barrier is severely compromised. This is manifest as ‘proteinuria’. Its magnitude can 
be assessed by measuring the amount of albumin, which appears in the urine over unit time; the sim-
pler measure, the urine albumin/creatinine ratio, can also be employed. In the second phase of disease, 
glomeruli become scarred or ‘sclerotic’ and this leads to the loss of total filtration surface. This occurs 
long after ADR has been cleared and it exemplifies the ‘progression of CKD’ often observed in clinical 
practice. This has two clinical outcomes: both the degree of proteinuria may fall and, at the same time, 
the GFR also falls. Given that an unchecked fall of GFR will ultimately lead to ESRD, minimally invasive 
measures which correlate with gross structural glomerular damage would be highly informative.
Importantly, we chose SCID mice in the current study with a longer-term view of using immuno-
compromised mice with drug-induced nephropathy as test beds for assessing the safety and efficacy of 
different types of human stem cells. The two minimally invasive technologies comprised firstly, a trans-
cutaneous electronic device for measuring the clearance from the blood of (FITC)-sinistrin, a molecule 
of approximately 4000 Da cleared by glomerular filtration10,11. This device can be applied in conscious 
animals, which is a key advantage, given the well-described confounding effects of general anaesthesia 
on GFR12,13. The second technology was multispectral optoacoustic tomography (MSOT). This imaging 
technology was used to measure the passage of a near infra-red dye, IRDye 800CW carboxylate (from 
now on referred to simply as IRDye), through the kidney parenchyma into the renal pelvis. Specifically, a 
recent report suggested that MSOT could effectively monitor renal clearance of IRDye in mice14. MSOT 
illuminates tissue with light pulses at multiple wavelengths and detects acoustic waves generated by the 
thermoelastic expansion which follows light absorption15,16. The technique is not harmful and offers very 
good temporal and spatial resolution in live animals; however, it requires the animals to be studied under 
general anaesthesia.
Results obtained with these techniques were compared with standard biochemical and histological 
indicators of kidney damage. This included 24-hour-albuminuria or urinary albumin-to-creatinine ratio, 
serum creatinine (SCr), blood urea nitrogen (BUN), and Picro-Sirius red (PSR) and Masson’s Trichrome 
staining in order to detect structural histological damage. Subsequently, we applied an extensive range 
of statistical tests to determine whether the transcutaneous device and MSOT are appropriate tools for 
monitoring kidney function. Furthermore, we assessed whether both technologies could be used to pre-
dict histological damage during progression to CKD in the ADR model.
Results
The half-life of transcutaneously measured FITC-sinistrin becomes significantly increased 
over the course of ADR-induced nephropathy. Kidney injury was induced by intravenous (iv) 
ADR administration once in 6 SCID female mice while 5 control SCID females received saline injec-
tion. The weights of ADR-administered versus control mice reached their lowest point one week after 
nephrotoxin administration. Over the next four weeks, weights in the ADR group returned towards time-
matched control values but did not attain them (Fig. 1A, S1A). To determine damage to the glomerular 
macromolecular barrier, we measured total 24-hour urinary excretion and the albumin:creatinine ratio 
on a weekly basis (Fig. 1B,C, S1B,C). Using either measure, albuminuria was significantly elevated in the 
ADR group at weeks 2 to 4, with attenuation at week 4 (Fig. 1B,C, Table S1A, S3). Similar effects have 
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been previously reported in ADR-induced SCID mice4,9,17. A linear mixed-effects (LME) model showed 
statistically significant linear and quadratic changes of albuminuria over time within the ADR group 
(p < 0.001 for both the linear and second degree terms, Table 1).
To assess changes in glomerular filtration over time with the transcutaneous device, we undertook 
serial measurements of FITC-sinistrin half-life over 4 weeks. Representative examples of clearance curves 
from control and ADR animals are shown in Fig. 2A–D. The FITC-sinistrin half-life in the ADR group 
was increased with statistical significance from week 2 onwards (Fig.  2E, Table S1A, S3). Given that 
GFR is inversely correlated to the FITC-sinistrin half-life10,18, these results suggest that GFR is slightly 
impaired 2 weeks after ADR administration and deteriorates further between weeks 3 and 4, reflect-
ing the progressive nature of the nephropathy19. An LME model revealed statistically significant linear 
changes in the FITC-sinistrin half-life within the ADR group over time, with an average increment of 
2.45 (= (0.02 + 0.33) × 7) minutes per week (p < 0.001). These changes were statistically different when 
compared with controls, in which no significant changes in half-life were detected (p = 0.76, Table  1). 
The levels of BUN and SCr as indicators of kidney function revealed no significant differences between 
the experimental control groups at week 5 (Figure S1D,E).
The passage of IRDye through the kidney measured using MSOT is delayed in ADR mice. To 
investigate the potential of MSOT for evaluating renal function in ADR mice, IRDye clearance was 
Figure 1. (A) Mean change in body weight of mice up to five weeks after adriamycin administration. 
Animals of the ADR group had a mean body weight loss of approximately 20% by week 1, while control 
animals had a mean body weight gain of 5%. (B) Mean albuminuria over 24 hours, measured weekly. ADR-
administered animals had a mean maximum of albuminuria of approximately 90 mg/24 h at 3 weeks, while 
in control animals urinary albumin stayed constant throughout the study at around 0.03 mg/24 h. (C) Mean 
albumin:creatinine ratio (alb:cr) measured weekly, showing similar temporal dynamics to 24 h albuminuria. 
Data points (circles = control, n = 5; squares = ADR-administered, n = 6) and bars show mean ± standard 
error. Asterisks indicate significance of mixed-design ANOVA models: p ≤ 0.01 (**), p ≤ 0.001 (***), see also 
Table S3.
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ALBUMINURIA (mg/24 h) FITC-SINISTRIN HALF-LIFE (min)
Changes over time (LME) Changes over time (LME)
Term Coef. estimate SE P-value Term Coef. estimate SE P-value
Group − 12.94 8.11 0.12 Intercept (min) 9.96 0.91 < 0.001
Group × Time (day) 8.34 1.3 < 0.001 Time (day) 0.02 0.07 0.76
Group × Time2 (day2) − 0.24 0.04 < 0.001 Time × Group (day) 0.33 0.07 < 0.001
Error terms Mean SD Error terms Mean SD
Random Error* 0.00 6.86 Random Error* 0.00 0.71
Residual* 0.00 4.64 Residual* 0.00 3.74
Table 1.  Statistical mixed-effects models that describe albuminuria and FITC-Sinistrin half-life over 
time. The model terms are listed with the corresponding coefficients estimates (Coef. estimate), standard 
error (SE) and p-value. The factor ‘Group’ is defined as 1 if the mouse belongs to the ADR group, and as 0 
otherwise. The error terms of the model are also reported. *Follows a normal distribution with mean zero 
and standard deviation (SD).
Figure 2. (A–D) Typical FITC-sinistrin kinetic curves (arbitrary units) in a control mouse at week zero 
(A), and four (B); and in an ADR-administered mouse prior to (C) and at four weeks post-adriamycin 
administration (D). (E) The mean half-life of FITC-sinistrin for the ADR-administered and control groups is 
shown weekly for four weeks. Data points (circles = control, n = 5; squares = ADR-administered, n = 6) and 
bars show mean ± standard error. Asterisks indicate significance of mixed design ANOVA models: p ≤ 0.05 
(*), p ≤ 0.01 (**), see also Table S3.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:13601 | DOi: 10.1038/srep13601
monitored in real-time at week 5, before killing for necropsy studies. Movies and snap-shot images 
taken prior to, and 15 s, 45 s, 1 min 30 s and 3 min after administration of IRDye showed that its passage 
through the kidney appeared to be delayed in ADR versus control mice (Fig. 3A, supplementary movie 
1, 2). More specifically, temporal colour maps of the clearance kinetics confirmed that in nephropathic 
mice, the dye took longer to transit from the kidney cortex to the papilla/pelvis region than in controls 
(Fig.  3B). Visualisation of the TMAX allows discrimination between the ADR and the control group, 
highlighted by the peak signal intensity in the cortex of the control animals appearing at ~30 s and 
visualised in yellow. By contrast, the yellow tone indicating 30 s peak signal intensity is absent in the 
ADR treated mice; instead, green colour tones visualise peak signal intensities that appear with a delay 
at around 1 min. Furthermore the papilla/pelvis region of control animals show peak concentrations 
from 1.5–3 minutes (green, blue, violet, red), whereas the ADR treated mice show peak concentrations 
in this region only after 3 minutes (violet, red, Fig. 3B). We determined the pharmacokinetics of IRDye 
clearance by calculating the TMAX delay between the renal cortex and pelvis (Fig. 3C,D, Table S1B), and 
the clearance half-life in the cortex, using exponential decay fitting (Fig.  3C,E, Table S1B). TMAX delay 
was significantly increased in the ADR-administered group versus controls (p = 0.015), and there was a 
non-significant increase in clearance half-life between these two groups (Fig. 3D,E; Table S2). However, 
equilibrium dialysis revealed that over 40% of IRDye bound to plasma proteins (Table S4), suggesting 
that the exponential decay might be shorter than expected in ADR mice due to leakage of plasma pro-
teins through the glomerular filtration barrier, thus leading to a potential underestimation of the true 
clearance half-life in the cortex.
Minimally invasively measured clearance kinetics of sinistrin and IRDye show a strong cor-
relation with glomerular histological damage. To visualise and measure structural damage, we 
made use of Picro-Sirius Red (PSR) staining which binds specifically to fibrillar collagen type I and 
III under polarising microscopy. Analysing PSR staining on parasagittal kidney sections from mice 
necropsied at week 5, we determined that ADR kidneys contained a subset (12–29%, across the whole 
experimental group) of glomeruli with lesions (Fig.  4B,C; Tables S1B, S2). In these glomeruli, there 
was a loss of capillary loops and extension of PSR staining into the glomerular tuft beyond the normal 
tree-like mesangial pattern. In control kidneys, such glomerular lesions were rarely detected (Fig. 4A). 
Quantification of total PSR staining (i.e. not confined to glomeruli) under bright field microscopy, and 
of fibrillar collagen under polarising microscopy, failed to show significant differences in ADR versus 
control kidneys (Fig. 4D,E, S2A,B; Tables S1B, S2). However, we noted the occurrence of proteinaceous 
casts together with flattened tubular epithelia in both PSR- and Masson’s Trichrome-stained ADR kid-
neys viewed under bright field microscopy (Figure S2B,D), but not in control kidneys (Figure S2A, C). 
These observations show that in this model, at this particular time point, glomerular damage is the 
predominant lesion, while tubulo-interstitial changes are much less prominent.
Next, we evaluated whether the two novel minimally invasive dye clearance methods we have used 
here to detect kidney filtration function, are suitable for long-term regenerative medicine therapy stud-
ies through their statistical association with detected glomerular damage. Importantly, since we had 
observed a wide range in the proportions of scarred glomeruli (as assessed by the above criteria) in the 
ADR kidneys, we questioned whether specific glomerular damage in individual mice was associated 
with specific measures of kidney function. Therefore, we examined the relationship in individual animals 
between glomerular histological lesions and (i) albuminuria, (ii) FITC-sinistrin half-life and (iii) IRDye 
excretion kinetics in individual animals (Fig.  5). In ADR mice, there was no significant association 
between glomerular histological damage (week 5) and the amount of albuminuria measured at the max-
imum (weeks 2–3) or at the final point of urine collection in week 4 (Table 2). Therefore, albuminuria 
is not a reliable measure of glomerular histological damage in this model. By contrast, assessment of the 
relationship between FITC-sinistrin half-life and the proportion of histologically damaged glomeruli 
revealed a significant positive correlation between FITC-sinistrin half-life values at week 4 and glomer-
ular damage at week 5 (coefficient = 0.94, p = 0.001; see Table 2).
When we assessed the relationship at 5 weeks between glomerular histological damage and IRDye 
clearance half-life, we found a significant association in the ADR group (coefficient = 0.12, p = 0.02; 
Table 2). Furthermore, the TMAX delay was significantly associated with glomerular histological damage 
in the ADR group (coefficient = 0.16, p = 0.002; Table 2). The coefficient suggests that an increment of 
60 seconds in TMAX delay is associated with an increment of glomerular histological damage of about 
10%.
Discussion
Here, we report for the first time the use of transcutaneous measurement of FITC-sinistrin decay 
and MSOT detection of IRDye clearance as measures of glomerular filtration function in SCID mice 
with ADR-induced nephropathy. Our albuminuria measurements strongly suggest that ADR-induced 
nephropathy featured a loss of glomerular macromolecular barrier integrity in SCID mice from week 2, 
peaking at week 3, similarly to recently published results4,9,17. In ADR mice, the FITC-sinistrin half-life 
was significantly prolonged from week 2. The fact that the half-life continued to rise thereafter in the 
ADR group is a strong indicator of a progressive loss in the ability of the kidneys to excrete small 
molecules from the circulation, i.e. a progressive decline in GFR. Previous studies have demonstrated 
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Figure 3. (A) MSOT images of a typical control (top) and ADR-administered (bottom) mouse before and 
after the administration of IRDye. Region of interests (ROIs) depicted in yellow (cortex) and red (papilla/
pelvis region). Times indicated above apply to both control and ADR-treated animal. (B) Temporal colour 
maps of control and ADR-administered mice reveal a delay in IRDye clearance kinetics in the treated 
mice. (C) Characteristic plot of mean pixel intensity (MSOT arbitrary units) from ROIs drawn around the 
renal cortex (black) and papilla/pelvis region (grey). (D,E) Graphs showing distribution of TMAX delay (D) 
and the excretion half-life in the cortex (E) in ADR-administered and control animals. Data points (D,E) 
represent individual animals (circles = control, n = 5; squares = ADR-administered, n = 6) and lines represent 
mean ± standard error. Asterisks indicate significance of two-sample t-tests: p ≤ 0.05 (*), see also Table S2.
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the accuracy and reliability of the transcutaneous measurement of FITC-sinistrin half-life as a measure 
of GFR in various strains of rats and mice10,11,18,20–23. Of note, although remaining elevated, the degree 
of albuminuria fell between weeks 3 and 4. This again might be explained by a loss in total filtration 
surface associated with glomerular damage as observed in week 5, consistent with the observed rise in 
FITC-sinistrin half-life during this period.
Using MSOT imaging, we showed here that IRDye is cleared in a dynamic fashion as it first appears 
in the kidney cortex and then transits to the renal pelvis, confirming a previous report14. The simplest 
Figure 4. Typical examples of normal (A) and abnormal (B) glomeruli imaged under bright field 
microscopy in 4 μm Picro-Sirius Red-stained paraffin sections at week five. On one kidney section per 
animal the percentage of abnormal glomeruli was determined (C). One whole kidney section per animal 
was photographed under bright field and polarised microscopy and the images were stitched together to 
produce one whole kidney image. On each whole-kidney image the percentage of PSR staining under 
bright field light (D) and the percentage of fibrillar collagen under polarised light (E) were quantified using 
image analysis software. Scale bars (A,B) represent 50 μ m. Data points (C,E) represent individual animals 
(circles = control, n = 5; squares = ADR-administered, n = 6) and lines represent mean ± standard error. 
Asterisks indicate significance of two-sample t-tests: p ≤ 0.01 (**), see also Table S2.
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interpretation of the TMAX delay of IRDye clearance we measured in the ADR versus control group, is 
that the glomerular clearance of this small molecule is impaired. The observation that some IRDye binds 
to plasma proteins, and that the ADR model features proteinuria, may have led to an underestimation 
of the true ‘TMAX delay’. In addition, it is possible that the passage of IRDye along the lumen of kidney 
tubules may be compromised in the ADR model but this will require further study.
Our BUN and SCr measurements revealed that these are not useful indicators of ADR-induced 
nephropathy at a time point when sinistrin clearance deviated most from normal. Both BUN and SCr 
measurements have been questioned as biomarkers for the early detection of human and rodent kidney 
disease at the histological level since they frequently identify abnormal kidney function only in the later 
stages of the diseases24,25. Previously, an increase in SCr in ADR-induced nephropathy has only been 
Figure 5. Correlation graphs showing the correlation of both control and ADR group data between the 
percentage of abnormal glomeruli and maximum observed albuminuria (A), FITC-Sinistrin half-life 
at week 4 (B), IRDye excretion half-life in the cortex at week 5 (C) and IRDye TMAX delay (D) at week 
5. Data points represent individual animals (circles = control, n = 5; squares = ADR-administered, n = 6). 
Trendlines for control (dashed line) and ADR-administered (solid line) animals are displayed.
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observed in male rodents, while in female rodents, SCr levels remained unchanged when compared to 
control animals, even though pathohistology clearly indicated the full spectrum of renal damage3,26–30.
Crucially, our observations that BUN and SCr fail to detect significant differences in kidney function 
at a time point when histological changes are clearly quantifiable, emphasises the need to develop novel 
molecular biomarkers that are better able to monitor renal health and assess the efficacy of therapeutic 
interventions, including regenerative medicine therapies24,31,32.
We conclude that transcutaneous measurements of FITC-sinistrin half-life provide a minimally inva-
sive method to repeatedly assess GFR in conscious mice, thus allowing for longitudinal evaluation of kid-
ney function. Furthermore, our analysis suggests that MSOT imaging has the potential to be employed 
for the repeated and minimally invasive measurement of kidney function in mice by assessing renal 
clearance of injected small near infrared dyes. The use of near infrared dyes with negligible plasma pro-
tein binding properties will further improve MSOT imaging performance for the measurement of renal 
clearance kinetics. Optoacoustic imaging can also be employed to track administered stem cells labelled 
with gold nanorods, expressing tyrosinase or near infrared fluorophores in whole animals33–40. Therefore, 
this imaging technology will be of high importance for preclinical studies in regenerative approaches to 
nephropathies as it will allow the detection of labelled cells in parallel with functional measurements of 
renal clearance kinetics.
In order to assess whether functional kidney data correlated with glomerular scarring, we performed 
histological analysis of sections by staining with PSR and Masson’s Trichrome. While SCID animals with 
ADR-induced nephropathy showed a strong elevation in the number of abnormal glomeruli at 5 weeks, 
at this time point we only observed occasional pathohistological changes in the tubulo-interstitial zone 
of ADR mice. Cortical glomerular and tubulo-interstitial damage have been reported previously in mice 
with ADR-induced nephropathy19,26,28,41,42.
Importantly, we aimed to statistically analyse whether any associations could be detected between glo-
merular histological damage and albuminuria, FITC-sinistrin half-life or IRDye clearance, respectively, 
in mice with ADR-induced nephropathy on the SCID background. Our evaluations provide evidence 
that FITC-sinistrin half-life and TMAX of IRDye clearance were strongly correlated with glomerular scar-
ring in SCID mice with ADR-induced nephropathy. We therefore conclude that FITC-sinistrin half-life 
and IRDye clearance (TMAX) measurements may be good predictors of glomerular histological damage. 
In contrast, neither peak albuminuria nor albuminuria at 4 weeks after ADR-induced nephropathy were 
significantly correlated with glomerular scarring, suggesting that urinary albumin measurements fail to 
provide an accurate reflection of the histological glomerular damage in this model at this time point.
In a recent report, rats with ADR-induced nephropathy were analysed with magnetic resonance imag-
ing to monitor changes in kidney function and histopathology during disease progression. This study 
is another example, similar to the one we report here, to demonstrate the feasibility of a longitudinal, 
minimally-invasive imaging technology as an approach to assessment of changes in the kidney over 
time43.
In conclusion, our results indicate that the minimally invasive technologies for detecting FITC-sinistrin 
half-life and IRDye clearance kinetics could be widely adopted for in vivo monitoring of models of RMT 
in progressive kidney disease. Each technology potentially allows recurrent testing in individual animals, 
maximising the information obtained as nephropathy and/or regenerative effects progress. The observa-
tions that sinistrin clearance and IRDye kinetics significantly correlate with the proportions of damaged 
glomeruli in individual animals, indicates that these minimally invasive measurements could markedly 
reduce animal numbers in preclinical models of nephropathy.
Materials and Methods
Animals. Female BALB/c severe combined immunodeficient (SCID) mice (Charles River, Margate, 
UK) were housed in individually ventilated cages at a 12 hour light/dark cycle, with ad libitum access 
to food and water. At age seven to eight weeks, ADR-induced nephropathy was induced in six mice 
Biomarker Coef. estimate SE P-value
AlbuminuriaMAX (mg/24 h) 0.04 0.05 0.45
Albuminuria4w (mg/24 h) 0.2 0.15 0.21
FITC-sinistrin half-life4w (min) 0.94 0.18 0.001
IRDye clearance half-life (s) 0.12 0.04 0.02
IRDye TMAX delay (s) 0.16 0.03 0.002
Table 2.  Table summarising the associations in the ADR group between abnormal glomeruli (5w) and 
the four biomarkers: albuminuria at the maximum observed and at four weeks, FITC-Sinistrin half-
life, IRDye clearance half-life, IRDye TMAX delay. The results included in this table were derived from the 
statistical models described in Table S5 by using contrast analysis. Each coefficient estimate indicates the 
change in percentage of abnormal glomeruli per unit change of the corresponding biomarker.
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by injecting once intravenously (iv) adriamycin (ADR, doxorubicin hydrochloride, Tocris, Bristol, UK) 
at 6.3 mg/kg body weight (BW) in 0.9% saline (Braun, Melsungen, Germany), while five control mice 
received saline. The optimal dose had been previously determined in a dose-finding study, and is sim-
ilar to previously reported adriamycin dose given to BALB/c SCID mice4,9,17. Mortality in the ADR-
administered group during the five-week study period was zero. Experimental animal protocols were 
performed in accordance with the approved guidelines under a licence granted under the Animals 
(Scientific Procedures) Act 1986 and approved by the University of Liverpool Animal Ethics Committee. 
BALB/c SCID mice were used in order to determine parameters for future preclinical regenerative med-
icine studies in mice with ADR-induced nephropathy.
Albuminuria, serum creatinine and BUN. To collect urine, mice were housed individually in 
metabolic cages (Tecniplast, Buguggiate, Italy) once a week for 24 hours (h). Despite being gradually 
acclimated to the metabolic cages, 24 h urine collection is stressful for mice, leading to weight loss of 
up to 1.5 g during the time spent in the cages. Because the mice on average weigh less than 20 g, it was 
necessary to omit urine collection at week five, since the long term anaesthesia for MSOT imaging is 
another stressful procedure for the mice. Total urine volume was measured and albumin levels were 
quantified using a Mouse Albumin ELISA Quantification Kit (Bethyl Laboratories, Montgomery, TX, 
USA) according to manufacturer’s instructions. Urinary creatinine (UCr) was quantified using a plate 
based colourimetric assay. Blood was collected via cardiac puncture after sacrifice, and separated into 
serum. Serum creatinine (SCr) and blood urea nitrogen (BUN) were quantified according to manu-
facturer’s instructions (Detect X Serum Creatinine Detection Kit, Arbor Assays, Ann Arbor, MI, USA; 
QuantiChrom Urea Assay Kit, BioAssay Systems, Hayward, CA, USA, respectively).
Histopathology. Kidneys were dissected at week 5, cut along the sagittal plane, and processed for his-
tology using standard methods. Sections (4 μ m) were stained with Picro-Sirius Red (PSR, Sigma-Aldrich, 
Dorset, UK) or Masson’s Trichrome following standard protocols. All glomeruli (on average 116 glomer-
uli) in one PSR-stained kidney section per animal were blindly scored for glomerular histological damage 
and the percentage of abnormal glomeruli calculated. Glomeruli were categorised as abnormal if the PSR 
staining extended beyond the confines of the mesangium into the glomerular tufts. These scarred glo-
meruli also featured obliteration of capillary spaces and adhesions of tufts to the Bowman capsule. Using 
one panorama kidney section per animal, fibrillar collagen was detected using polarised microscopy, 
while PSR-staining in the cortex was captured by bright field microscopy. Images were stitched together44 
and image analysis software (Fiji) was used for quantification.
Transcutaneous FITC-sinistrin decay. FITC-sinistrin half-life was measured weekly in all animals11. 
In short, the transcutaneous device (Mannheim Pharma & Diagnostics GmbH, Mannheim, Germany) 
was fixed to the depilated skin on the back of mice using a double-sided adhesive patch (Lohmann, 
Neuwied, Germany). Transcutaneous measurement started with background reading one to three 
min before 0.3 mg/g BW FITC-Sinistrin (Fresenius Kabi, Linz, Austria; diluted in 0.9% saline; Braun, 
Melsungen, Germany) was administered iv. Animals were allowed to fully recover and move freely until 
transcutaneous measurement was stopped after 90 minutes (min). Using a 1-compartment model, the 
half-life of FITC-Sinistrin was calculated from the transcutaneously measured kinetics (Figure S3)11.
Measuring the clearance of IRDye 800CW carboxylate using MSOT. Five weeks after adria-
mycin or saline administration, anaesthetised (isoflurane) mice had hair removed from the abdomi-
nal region and were imaged in the inVision 256-TF MSOT imaging system (iThera Medical, Munich, 
Germany) using a multispectral protocol for 30 min (rate of 10 frames per second using wavelengths: 
700, 730, 760, 775, 785, 800 and 850 nm, and averaging 20 consecutive frames to minimise influences of 
motion). Five min into the imaging mice received 200 μ l (20 nmol) IRDye 800CW carboxylate (LI-COR, 
USA) in 0.9% saline through a tail vein cannula over a period of 10 seconds (s). Data was reconstructed 
and multispectral processing performed to resolve signals for the IRDye, including gradient scaling for 
each animal at a time prior to the injection of the IRDye. Regions of interest (ROIs) drawn around renal 
cortex and the renal papilla-pelvis region (in short: pelvis) of the right kidney of each mouse were used 
to determine the time between the mean peak pixel intensity (TMAX) in the cortex and the pelvis (TMAX 
delay). Exponential decay was fitted for mean cortex pixel intensities to determine the characteristic 
excretion half-life.
To depict the temporal dynamics of IRDye clearance in colour code, a Matlab routine was developed 
to process a stack of images and calculate a composite image on a pixel-by-pixel basis of TMAX, defined 
as the time (or frame number in the stack) at which the highest intensity was recorded at that pixel. A 
pseudocolor was applied to display this time (or frame number) per pixel as different colours on the 
spectrum colour scale. Image stacks were typically composed of 15 images. With a temporal resolution 
from in vivo imaging of approximately 16 s this equated to approximately 4 min of imaging data after 
injection that were used for temporal analysis. A CMAX image as a maximum intensity projection was 
computed of the same image stack. ImageJ was used to amplitude modulate the pseudocoloured TMAX 
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image using the CMAX in order to dim areas with little contrast and therefore to reduce background noise 
in the TMAX caused by an absence of substantial temporal change in a certain pixel.
Statistical analyses. Linear mixed-effects (LME) models were fitted to characterise changes of albu-
minuria and of FITC-sinistrin half-life over time. The advantage of using a linear mixed-effects model 
is that the correlation between measurements across time points within mice is taken into account in a 
term called the random term. Differences in albuminuria and FITC-sinistrin half-life between the treat-
ment and control group (e.g., differences in linear or quadratic changes over time) were subsequently 
tested using these models.
Multiple linear regression models were applied to test whether glomerular histological damage was 
associated with transcutaneous measurements of albuminuria (maximum observed values and week 4 
values), FITC-sinistrin half-life (week 4 values), TMAX delay and excretion half-life of IRDye (the latter 
measured at 5 weeks).
Independent t-tests were applied to compare measures of kidney function at 4 weeks and of 
post-mortem histology measurements at 5 weeks between the control and the treatment group. The 
assumptions of normality and homogeneity of variances were checked.
Plasma Protein Binding of IRDye. A dye-protein stock solution was prepared by incubating of 
2 ml IRDye (10 μ mol) with 8 ml Sprague Dawley rat plasma Li Heparin (Innovative Research, Novi, MI, 
USA) in phosphate buffered saline (PBS) at 37 °C, while 2 ml PBS was incubated with 8 ml rat plasma as 
control. Plasma protein-binding measurements were performed by equilibrium dialysis of PBS against 
dye-protein stock solution (or control stock solution) using a two-chamber dialysis set-up (Equilibrium 
Dialyzer, Havard Apparatus, Holliston, MA, USA)45,46. After 24 h the absorption of IRDye in PBS and 
plasma were determined in three independent measurements by absorption spectroscopy in a microplate 
reader (Tecan Infinite M200) and the concentrations of IRDye was calculated on the basis of the corre-
sponding molar absorption coefficients (Figure S4, Table S3).
Plasma protein binding (PPB) of IRDye in percent was determined by averaging three independent 
measurements and following the equation of Beer-Lambert law:
( )− ( ) / ( ) + ( ) ∗[A plasma A PBS ] [A plasma A PBS ] 100
where A is denoted as corresponding to UV absorption.
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